The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Advocates Visit D.C. to Act for Arthritis

Rheumatology Advocates Visit D.C. to Act for Arthritis

September 20, 2017 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR/ARHP’s annual fly-in to D.C. (#Act4Arthritis) was a huge success. More than 100 ACR/ARHP members and patients from across the nation attended meetings on Capitol Hill to advocate for people living with rheumatic diseases. In all, our advocates visited 138 Senate and House offices.

You Might Also Like
  • Help the ACR Bring Its Message to the Hill
  • Rheumatology Champions Call for Lower Prescription Drug Costs, and More in Meeting with Congressional Legislators
  • Rheumatology Advocates to Visit Capitol Hill
Also By This Author
  • 2019 MIPS Deadline Extension & Policy Update

This year’s fly-in on Sept. 25–26 coincided with the second-annual Rheumatic Disease Awareness Month (#RDAM): September 2017. RDAM seeks to improve policymakers’ understanding and awareness of rheumatic diseases, and the unique and significant healthcare challenges facing Americans living with these chronic, painful and debilitating conditions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

During our visits, we discussed three policy issues currently affecting rheumatology patients and their ability to access quality, affordable healthcare. You can learn more about the issues below and take action from home.

  1. Reduce Patients’ Out-of-Pocket Expenses
    H.R. 2999, the Patients’ Access to Treatments Act (PATA), has been introduced in the House of Representatives to limit patients’ cost-sharing requirements under specialty-tier drug pricing systems common among insurers and to increase access to life-saving biologics. We are asking Senate members to introduce PATA in the Senate and to request a Senate hearing on the use of specialty-tier drug pricing by insurers. You can help achieve this by asking your members of Congress to support PATA and combat the use of specialty tiers.
  1. Repeal Medicare Therapy Caps
    In 1997, as part of the Balanced Budget Act, Congress instituted arbitrary caps on Medicare outpatient therapy services, including physical therapy, speech language pathology and occupational therapy, in an attempt to achieve enough cost savings to balance the federal budget. These therapy caps threaten the health and well-being of millions of Medicare patients who live with rheumatic diseases and rely on vital therapy services to manage their chronic conditions. Therapy caps force patients to bear 100% of the cost of care—something many cannot afford. Fortunately, Congress has acted 16 times to temporarily prevent these caps’ implementation, with the current exemption expiring on Dec. 31, 2017. Permanent repeal of therapy caps via the Medicare Access to Rehabilitation Services Act (H.R. 807/S. 253) has overwhelming bipartisan support. You can add your voice by asking your patients to urge your member of Congress to co-sponsor H.R. 775 and get rid of these caps once and for all.
  1. Change the Role of Pharmacy Benefit Managers in Prescription Drug Pricing
    It is vital that lawmakers come to understand the role that pharmacy benefit managers (PBMs) play in the pricing of prescription drugs:
  • PBMs can drive up drug costs by creating market pressure for higher list prices (the higher the list price, the higher the rebate).
  • PBMs use their position to negotiate contracts with manufacturers, insurers and pharmacies that maximize their profits, often at the expense of patients.
  • PBMs use spread pricing in which they charge an insurer a different amount for given drugs than what they reimburse the pharmacy for dispensing the drugs. This may be kept as extra profit by the PBM.
  • PBMs use drug-switching practices, which increase profits by steering patients toward expensive medications whose manufacturers pay rebates to PBMs for promoting a particular drug.

The ACR and other agencies/partners are working to combat PBMs’ ability to balloon the cost of necessary treatment to patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

You can take action today by educating your lawmakers on PBMs and asking them to consider legislation combating methods that limit access to care.

A Note of Thanks
Thank you to our physician, healthcare provider and patient advocates, who lend their time and voices to fight for affordable and accessible rheumatology care, both in D.C. and from home.

 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Multi-Page

Filed Under: Legislation & Advocacy Tagged With: 2017 ACR/ARHP annual fly-in, Act for Arthritis, Medicare therapy caps, Patients’ Access to Treatments Act (PATA), pharmacy benefit managers (PBMs), Rheumatic Disease Awareness Month (RDAM)

You Might Also Like:
  • Help the ACR Bring Its Message to the Hill
  • Rheumatology Champions Call for Lower Prescription Drug Costs, and More in Meeting with Congressional Legislators
  • Rheumatology Advocates to Visit Capitol Hill
  • American College of Rheumatology (ACR) Advocates for Improved Access to Critical Treatments

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.